Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 451 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
How did AXGN's recent EPS compare to expectations?
The most recent EPS for AxoGen Inc is $0.07, not beating expectations of $0.07.
How did AxoGen Inc AXGN's revenue perform in the last quarter?
AxoGen Inc revenue for the last quarter is $0.07
What is the revenue estimate for AxoGen Inc?
According to 11 of Wall street analyst, the revenue estimate of AxoGen Inc range from $71.08M to $64.68M
What's the earning quality score for AxoGen Inc?
AxoGen Inc has a earning quality score of B+/51.075703. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does AxoGen Inc report earnings?
AxoGen Inc next earnings report is expected in 2026-07-27
What are AxoGen Inc's expected earnings?
AxoGen Inc expected earnings is $58.87M, according to wall-street analysts.
Did AxoGen Inc beat earnings expectations?
AxoGen Inc recent earnings of $61.45M beat expectations.